Last updated on February 2015

Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature

Brief description of study

The study was evaluated as the optimal dose for the treatment of SGA short stature children by Pegylated Somatropin, initially evaluated its efficiency and safety for the treatment of SGA short stature children and provided scientific, reliable basis for phase III clinical trials for dose selection.

Detailed Study Description

This was a multicenter, randomized phase II study, half of participants will receive the high dose, while the other half will receive the low dose.

Clinical Study Identifier: NCT02375620

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.